Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

In this retrospective study conducted at a trichology clinic, the off-label use of upadacitinib for at least 24 weeks was found to have a promising efficacy and safety profile for treating severe alopecia areata in adolescents.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This study found that Finasteride significantly reduced the proliferation of acute myeloid leukemia cell lines by inhibiting androgen receptor activity.

In this study, researchers found that cepharanthine significantly inhibited the growth of non-small cell lung cancer cells by inducing apoptosis through ROS generation and altering multiple signaling pathways, suggesting potential as a novel lung cancer treatment.

This study found that Black patients with alopecia areata showed an average 20% reduction in scalp involvement after JAK inhibitor therapy, indicating positive treatment outcomes in this group.

This study reported that five patients with alopecia areata achieved satisfactory results using 15 mg of Upadacitinib daily after conventional treatments had failed, without experiencing adverse events.

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

This article discusses the cutaneous side effects of erlotinib, an EGFR inhibitor, in a patient with non-small cell lung cancer, reporting nonscarring alopecia and indicative scalp biopsy findings.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

This study describes a newly recognized skin reaction associated with dasatinib, nilotinib, and ponatinib, marked by a lichenoid exanthem with severe pruritus that may necessitate discontinuation of therapy.

In this study, baricitinib was used as monotherapy to treat a 21-year-old woman with severe alopecia areata, resulting in significant hair regrowth and reduced alopecia severity within three months, suggesting its effectiveness and potential as a robust treatment option for this condition.

Baricitinib helps regrow hair in teens with severe alopecia areata.

In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.

This case report presents the first instance of a pediatric alopecia areata patient switching from baricitinib to ritlecitinib, demonstrating favorable clinical outcomes, suggesting a potential new treatment pathway for children with severe cases of this condition.

This study observed that JAK inhibitor therapy may be safely administered to patients with alopecia areata and latent HBV or stable TB, without reactivation of these infections, when appropriate monitoring and prophylaxis are used.

In this study, researchers examined Baricitinib's role as a treatment for Alopecia Areata, contrasting it with conventional therapies, and found that while effective, Baricitinib may cause adverse reactions depending on individual patient health histories.

In this study, baricitinib was well tolerated and led to clinical improvement in patients with treatment-resistant alopecia areata in a real-world clinical setting, suggesting it may be a potential treatment option.

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

This source reports that the approval of baricitinib and ritlecitinib, which are JAK inhibitors, has marked a significant advancement in treating severe alopecia areata (AA), and suggests that additional treatments with new mechanisms may further improve patient outcomes in the future.

This case report highlights an instance of nilotinib-induced keratosis pilaris without alopecia or pruritus, emphasizing the need for awareness to optimize patient outcomes.

This article highlights disparities in the prevalence of alopecia areata among people with skin of color and suggests this information could help dermatologic providers address challenges in treating this population.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.

This study reported that tofacitinib may be a promising treatment for alopecia areata in adolescents, showing significant hair regrowth with mild adverse effects in a retrospective review.

This review discusses the approval of deuruxolitinib, an oral JAK inhibitor, by the FDA in July 2024 for treating severe alopecia areata in adults, highlighting its role as the third approved oral treatment option alongside baricitinib and ritlecitinib.

This study found that oral baricitinib treatment led to hair regrowth in patients with alopecia areata, as observed in two phase 3 trials.

In this case study, a patient with refractory oral lichen planus experienced marked improvement within one month of daily treatment with baricitinib, contributing to the evidence supporting the use of JAK inhibitors for lichen planus.